Tata Capital Healthcare Fund II (TCHF II) has channelled up to $10 million into Mumbai’s Apex Kidney Care Private Ltd (AKC) to bolster its dialysis service expansion throughout India. Although the exact equity share acquired by the Tata Group subsidiary in the dialysis chain remains undisclosed, the funds are primarily earmarked for increasing the private sector footprint, including standalone centers, in-hospital units, and home dialysis services.

Indranil Roy Choudhury, the Group CEO of Apex Kidney Care, highlighted a medium-term capital expenditure projection of Rs 150 crore. Currently, AKC operates 6 standalone units, aiming to increase this figure beyond 60 in the coming years. Additionally, the company manages 61 in-hospital centres and oversees 84 centres under the Public-Private Partnership (PPP) model, in collaboration with governmental and municipal entities.

Vamesh Chovatia, a partner at TCHF II, emphasised the fund’s comprehensive investment strategy, particularly in backing enterprises like AKC that address evident healthcare deficiencies.

Staggering statistics reveal that India hosts approximately 2 million Chronic Kidney Disease (CKD) Stage-5 patients, with the addition of 2,00,000 to 2,20,000 CKD-5 patients annually. Presently, India witnesses around 21 million dialysis sessions every year, which tragically only covers about 11 per cent of the nation’s annual requirement, as per the assessment of Tata Healthcare Fund.

For context, TCHF is a progressive private equity fund specialising in India’s healthcare and life sciences domain, sponsored by Tata Capital Ltd. With a collective investment of nearly US$ 200 million across TCHF I (2012) and TCHF II (2022), the fund has ventured into 16 companies, successfully making exits from 6.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.